Showing results (11-20 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|October 17, 2014
A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinomaJennifer J Knox, Rui Qin, Jonathan R Strosberg, et al.
Investigational New Drugs|October 23, 2015
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutationPierre Combe, Laure Chauvenet, Marie-Aude Lefrère-Belda, et al.
Investigational New Drugs|October 23, 2015
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumorsAutumn J McRee, Hanna K Sanoff, Cheryl Carlson, et al.
Investigational New Drugs|May 9, 2016
Peloruside A, a microtubule-stabilizing agent, induces aneuploidy in ovarian cancer cellsAriane Chan, A Jonathan Singh, Peter T Northcote, et al.
Investigational New Drugs|January 1, 1986
Activity of 2-fluoro-Ara AMP against gynecologic tumors in the soft agar assayJ A Ajani, B Tomasovic, G Spitzer, et al.
Investigational New Drugs|August 12, 2015
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumorsAkiyoshi Kasuga, Kazuhiko Nakagawa, Fumio Nagashima, et al.
Investigational New Drugs|March 15, 2016
Peptide aptamer identified by molecular docking targeting translationally controlled tumor protein in leukemia cellsOnat Kadioglu, Thomas Efferth
Investigational New Drugs|March 11, 2016
Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumorsManisha H Shah, Paul Lorigan, Mary E R O'Brien, et al.
Investigational New Drugs|November 20, 2012
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumorsA H Awada, H Dumez, A Hendlisz, et al.
Investigational New Drugs|January 6, 2015
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancerDaniel P Petrylak, Jitendra G Gandhi, William R Clark, et al.
Pageof 372